Welcome, Guest. Please login or register.
October 03, 2022, 05:02:29 am

Login with username, password and session length


Members
  • Total Members: 36695
  • Latest: Libra84
Stats
  • Total Posts: 766167
  • Total Topics: 65356
  • Online Today: 116
  • Online Ever: 5484
  • (June 18, 2021, 11:15:29 pm)
Users Online
Users: 2
Guests: 111
Total: 113

Welcome


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Do I Have HIV?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: A Decade After Approval, PrEP Hasn’t Reached its Full Potential  (Read 387 times)

0 Members and 1 Guest are viewing this topic.

Online Jim Allen

  • Administrator
  • Member
  • Posts: 19,490
  • Twitter @JimAllenDublin
    • HIV Lessons

https://www.poz.com/article/decade-approval-prep-reached-full-potential

The prevention pills—and newer methods—have averted countless HIV cases, but they still aren’t reaching everyone who could benefit.

Quote
The advent of PrEP is credited with helping reduce HIV incidence over the past decade. According to the CDC, an estimated 34,800 people acquired HIV in 2019, after remaining stable at around 50,000 for many years. (HIV diagnoses fell steeply in 2020, but that could in part be attributable to decreased testing due to the COVID-19 pandemic.)

PrEP uptake started out low but accelerated quickly, especially among white gay and bisexual men. But Black and Latino men who have sex with men, cisgender women and transgender people have not been as eager to embrace PrEP as a prevention strategy.

Truvada (TDF/FTC) contains two drugs, tenofovir disoproxil fumarate and emtricitabine, that are widely used for HIV treatment. The benefits of TDF/FTC for PrEP were first demonstrated in the iPrEx trial, which found that the daily pills reduced the risk of HIV acquisition by 42% overall for gay and bisexual men and transgender women, but this rose to 92% for participants who had blood drug levels indicating good adherence.

The Partners PrEP study, which enrolled mostly heterosexual serodiscordant couples in Kenya and Uganda, found that daily TDF/FTC reduced the likelihood of HIV acquisition by 75%. Another study of heterosexual men and women in Africa, TDF2, showed a 62% risk reduction. In contrast, the Fem-PrEP study did not show a significant protective effect for high-risk African women, but participants’ blood drug levels were low, indicating less than optimal adherence.

In 2014, researchers first reported results from the French Ipergay trial, showing  that “on-demand” TDF/FTC taken before and after sex—known as PrEP 2-1-1—is also highly effective. In fact, the French PREVENIR study found that intermittent PrEP works as well as daily pills. PrEP 2-1-1 involves taking two doses of TDF/FTC between two and 24 hours before anticipated sex, one dose 24 hours after the initial double dose and a final dose 24 hours after that.

Initially, the high cost of Truvada and limited insurance coverage were barriers. But in 2019, the U.S. Preventive Services Task Force strongly recommended TDF/FTC PrEP for men and women at high risk of acquiring HIV, which meant that insurers were required to cover it. And in early 2021, cheaper generic versions of TDF/FTC came on the market in the United States. But Descovy and Apretude are still costly.

As POZ previously reported, 9 out of 10 gay and bisexual men at high risk for HIV were aware of PrEP, but only a third were using it in 2017. Black and Latino men who have sex with men were less likely to know about PrEP and less likely to use it than white and Asian men. In 2019, the CDC reported that 63% of eligible white people (not just gay and bi men) were receiving PrEP, but this fell to just 8% of Black people and 14% of Latinos.

PrEP adoption has been slow among women, but research points to ways to improve uptake. One recent study found that Black women said they would prefer PrEP injections over daily pills—but they don’t want to be rushed into a decision. And for trans women, recent data show that those with a gender-affirming provider are more likely to use PrEP.

But now there are new threats. A conservative lawyer in Texas, known for his work to restrict abortion access, recently filed a federal lawsuit to limit insurance coverage of PrEP. This is only one of several legal challenges against HIV services and health care access for LGBTQ people.

In order to increase PrEP access, Matthew Rose, a Black gay man who spoke in favor of PrEP approval in 2012, recommends community education and awareness campaigns, countering mistrust of the health care system, training more culturally competent providers, strengthening the health care infrastructure in the South (which accounts for a growing proportion of HIV cases), improving health care access in rural communities and better access for people who use drugs. Adapting service delivery to reach people of color could include primary care and family planning clinics, pharmacies, faith-based settings, youth centers, and hair salons and barbershops.
HIV 101 - Everything you need to know
HIV 101
Read more about Testing here:
HIV Testing
Read about Treatment-as-Prevention (TasP) here:
HIV TasP
You can read about HIV prevention here:
HIV prevention
Read about PEP and PrEP here
PEP and PrEP

 


Terms of Membership for these forums
 

© 2022 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.